Bellberry Donation Model
Bellberry’s not for profit status has been important to Bellberry’s Directors from the outset as they recognised the benefits research has on the health outcomes for Australians. Since its inception, the Company’s altruistic model has seen the operational functions of the business supported first and any surplus money donated to human medical research undertaken within Australia.
The Directors are very proud that more than $3.5 million has been donated to Australian research since 2004.
How are donation recipients selected?
The Board recognises that the selection of appropriate research is better placed with organisations that have appropriate expertise and selection processes in place. As a result, applications for funding are not accepted. The donations focus on research projects from the NHMRC round of grants and are provided to assist PhD students and researchers within the university sector. Approaches are made by the Directors to a single university on the basis that a grant will be made to the university. The university then determines which of the relevant NHMRC grant applications should receive the funding.
Bellberry provided support for ongoing initiatives; PRAXIS Australia, the PICF Project, CT:IQ (for a full update on the five CT:IQ projects for 2018/19 please visit the CT:IQ website), the Bellberry-Viertel Research Fellowships and the SAHMRI Bellberry Molecular Imaging Program.
In November Bellberry hosted the ‘Challenges of Valuing and Paying for Combination Therapies in Oncology’, Scientific Congress, Sydney (18-20 Nov). This significant event included a presentation of the issues and a discussion of the options for managing these challenges, by an international panel of experts from Australia, USA, Canada, Europe, Singapore and Japan. The Scientific Advisory Committee was chaired by Emeritus Professor Lloyd Sansom AO.
Bellberry continued support for the following professional bodies:
- AAHMS (Aust Academy of Health and Medical Sciences) Conference – Platinum Sponsorship
- ACTA International Clinical Trial Conference – Gold Sponsorship
- ASCEPT Joint Scientific Meeting, NZ – Major sponsor
Bellberry also continued its collaboration with SAHMRI to provide the Bellberry Molecular Imaging Program which was launched in 2016 and supports South Australia’s only cyclotron housed at SAHMRI. This project that will allow the development of a series of diagnostic agents that will enhance SAHMRI’s ability to deliver improved healthcare, clinical trial capacity and translational health outcomes.
In 2018 Bellberry also gave support to the QUT (Queensland University of Technology) Faculty of Health with the launch of the 3-year Bellberry Biomedical Ethics student prize.
Bellberry also continued to support professional bodies and were meeting sponsors for AAHMS (Australian Academy of Health and Medical Sciences), ACTA (Australian Clinical Trials Alliance) and ASCEPT.